SCHEMBL2117367

SCHEMBL2117367

Cc1ccc(-c2cnco2)cc1NS(=O)(=O)c1ccco1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EDNRA P25101 2/20 0.46
POLB P06746 1/20 0.45
KMT2A Q03164 1/20 0.45
CCR2 P41597 4/20 0.44
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
PSEN1 P49768 1/20 0.43
PSEN2 P49810 1/20 0.43
APH1B Q8WW43 1/20 0.43
NCSTN Q92542 1/20 0.43
APH1A Q96BI3 1/20 0.43
PSENEN Q9NZ42 1/20 0.43
TRIM24 O15164 1/20 0.43
PFKFB3 Q16875 2/20 0.42
PFKFB4 Q16877 1/20 0.42
LMNA P02545 1/20 0.41
PKM P14618 1/20 0.41
EDNRB P24530 1/20 0.41
SGK1 O00141 1/20 0.41
CYP11B1 P15538 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2119449 0.81 CYP3A4 (0.46) EDNRAPOLBKMT2ACYP3A4CYP2D6
SCHEMBL2117500 0.81 EDNRA (0.44) EDNRAPOLBKMT2ACYP3A4CYP2D6
SCHEMBL2118650 0.79 KDM4E (0.55) EDNRAPOLBKMT2ACCR2
SCHEMBL2117134 0.79 SLC40A1 (0.46) EDNRAPOLBKMT2ACYP3A4CYP2D6
SCHEMBL2118685 0.79 POLB (0.57) POLBKMT2ACYP3A4CYP2D6PSEN1
SCHEMBL2120014 0.79 POLB (0.51) EDNRAPOLBKMT2ACYP3A4CYP2D6
SCHEMBL2117806 0.79 CCR2 (0.44) POLBKMT2ACCR2TRIM24SGK1
SCHEMBL2121436 0.79 POLB (0.51) EDNRAPOLBKMT2ACYP3A4CYP2D6
SCHEMBL2119257 0.79 POLB (0.48) EDNRAPOLBKMT2ACYP3A4CYP2D6
SCHEMBL2117332 0.79 KCNJ1 (0.44) EDNRAPOLBKMT2ACYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE ELARA PHARMACEUTICALS GMBH (DE) 2012-04-19 US disclosed
EP-2382190-A1 TOLUIDINE SULFONAMIDES AND THEIR USE AS-INHIBITORS European Molecular Biology Laboratory (EMBL) (DE) 2011-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE HIF1A, HIF1AN, EGLN3 EDNRA 180/4885POLB 1880/4885KMT2A 290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.